Azitra (AZTR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 Jun, 2026Executive summary
The annual meeting scheduled for June 4, 2026, was adjourned due to lack of quorum, with only 17% of shares represented versus the required 33 1/3%.
The meeting will reconvene virtually on June 15, 2026, allowing additional time for shareholders to review proxy materials and vote.
Shareholders of record as of April 24, 2026, remain eligible to vote at the reconvened meeting.
No changes have been made to the proposals to be voted on at the reconvened meeting.
Voting can be completed by mail, internet, telephone, or during the live webcast on June 15, 2026.
Voting matters and shareholder proposals
Proposals to be voted on remain unchanged from those outlined in the definitive proxy statement filed May 8, 2026.
Shareholders who have already voted and do not wish to change their vote need not take further action.
Beneficial owners are encouraged to contact their bank or broker to ensure voting instructions are provided.
Board of directors and corporate governance
The Board of Directors and management request prompt submission of proxies by eligible shareholders.
Latest events from Azitra
- Engineered skin therapies target major unmet needs in dermatology with strong clinical momentum.AZTR
Corporate presentation - Q2 2026 net loss rose to $3.35M; cash at $6.7M; clinical pipeline advanced; capital needs persist.AZTR
Q2 2026 - Annual meeting adjourned to June 15, 2026, with unchanged proposals and ongoing R&D initiatives.AZTR
Proxy filing - Precision dermatology pipeline advances with engineered bacteria and key 2026 milestones ahead.AZTR
Corporate presentation - Advancing engineered skin microbiome therapies for rare and common dermatological conditions.AZTR
Corporate presentation - Narrowed net loss to $9M, advanced clinical trials, and raised $15M in new funding.AZTR
Q4 2024 - Net loss rose 5% to $3.1 million in Q1 2025; more funding is needed for clinical progress.AZTR
Q1 2025 - Net loss narrowed in Q2 2024 as $10M financing supports advancing clinical pipeline.AZTR
Q2 2024 - Net loss narrowed to $1.0 million, but cash may not last twelve months.AZTR
Q3 2024